Abstract:
Provided are a graphene hydrogel, graphene hydrogel nanocomposite materials, and a preparation method thereof, wherein the graphene hydrogel includes pores between laminated graphene sheets, and the pores contain moisture. In addition, the graphene hydrogel nanocomposite materials include nanoparticles and porous pores between laminated graphene sheets, and the pores contain water.
Abstract:
Provided is a probe system for low-temperature high-precision heat transport measurement, the probe system including a sample loader where a sample is loaded. In the probe system for low-temperature high-precision heat transport measurement, the sample loader includes a first frame including a sample loading space, and a second frame including an open end coupled to the first frame to accommodate the sample loading space.
Abstract:
A method of forming a compound structure according to embodiments of the present disclosure comprises loading a metal precursor on a substrate, providing a chalcogen precursor to the substrate, and reacting the chalcogen precursor with the metal precursor. The metal precursor comprises transition metal nanoparticles. The compound structure has a 2-dimensional structure.
Abstract:
The present invention relates to the preparation of an antibody analogue capable of being activated reversibly, and uses thereof, and provides a fusion protein comprising an inactive first fragment of an antibody analogue is fused to a stimulus-induced dimerization protein.
Abstract:
The present invention relates to a pharmaceutical composition for preventing or treating attention deficit/hyperactivity disorder (ADHD), including SNAP5114 as an active ingredient. A Git1 gene-deficient hetero (+/−) mouse, confirmed to have increased amount of GABA in the brain striatum that controls hyperactivity, can be used as an animal model of ADHD, and by confirming that hyperactivity is ameliorated by administering SNAP5114 to the Git1 gene-deficient hetero (+/−) mouse, SNAP5114 is provided as a therapeutic agent for ADHD.
Abstract:
The present invention relates to a method and kit for isolating an extracellular vesicle (EV) from a biological sample using fractional precipitation. According to the method and kit, rapid isolation is possible, and an EV can be effectively isolated from various types of biological samples regardless of the sample sources. Unlike a method for isolating an EV on the basis of an existing precipitation method, the present invention can easily remove a salt by washing, and, thus, has the benefit of being able to isolate a highly pure EV with a high yield rate and can be applied to both small-scale EV isolation in research and diagnostic fields and large-scale EV isolation for industrial applications.
Abstract:
The present invention relates to a method for manufacturing a monocrystalline metal foil and a monocrystalline metal foil manufactured thereby, the method comprising the steps of: fixing each of the ends of a polycrystalline metal foil to electrodes; and heat-treating the fixed polycrystalline metal foil to manufacture a monocrystalline metal foil.
Abstract:
The present invention relates to a polymeric gel comprising crosslink points, which are dissociated in response to nitrogen monoxide, and to a method for preparing a hydrogel, the method comprising the steps of: a) polymerizing a mixture of monomers comprising a monofunctional hydrophilic monomer and a monomer comprising a plurality of functional groups comprising an o-phenylenediamine residue; and b) separating a hydrogel formed by the polymerization.
Abstract:
The present invention relates to a deglycosylated LRG1 glycoprotein and a LRG1 glycoprotein variant, and a use thereof. The deglycosylated LRG1 glycoprotein and LRG1 glycoprotein variant of the present invention exhibit effects of angiogenesis, nerve growth and nerve regeneration that are superior to those of conventional LRG1 glycoproteins, and thus a composition containing thereof is effective in preventing and treating vascular erectile dysfunction, ischemic heart/brain/peripheral vascular diseases, diabetic vascular complications, neurogenic erectile dysfunction, diabetic neurologic complications, post-operative/post-traumatic peripheral nerve damage, ischemic diseases including neurodegenerative diseases, peripheral nerve diseases, erectile dysfunction and/or neurodegenerative diseases.
Abstract:
According to the present invention, an organic light-emitting composite and a method of manufacturing the organic light-emitting composite are provided. According to exemplary embodiments, an organic light-emitting composite includes a polymer matrix; a first light-emitting material provided in the polymer matrix; and a second light-emitting material provided in the polymer matrix and obtained by oxidizing the first light-emitting material, wherein the second light-emitting material may have the same molecular weight as that of the first light emitting-material.